Endocannabinoid signaling also modulates progesterone production in the luteal phase, and heavy use has been linked to luteal phase defect in some cohorts. A 2024 study in the journal Fertility & Sterility reported that women with serum THC above 5 ng/mL at baseline had a 1.8x higher odds of irregular cycles. These hormonal shifts can thin the endometrial lining, reducing the window for implantation. Clinics such as CCRM Fertility and Reproductive Medicine Associates now routinely flag cannabis use in intake questionnaires and adjust protocols accordingly. The ASRM outlines current guidance on cannabis and reproductive health.
Impact on Ovarian Reserve and Egg Quality
Research from 2023 and 2024 suggests that cannabinoids may accelerate ovarian aging by altering mitochondrial function in oocytes. Women with a history of heavy cannabis use showed a lower antral follicle count and anti-Müllerian hormone levels in some observational studies, though causation remains under investigation. Companies like Alife Health and Univfy are incorporating lifestyle data, including cannabis use, into their ovarian reserve prediction models. The NICHD provides data on factors affecting ovarian reserve.
In vitro fertilization labs report that embryos derived from oocytes exposed to high THC concentrations in culture show altered gene expression related to cell division. While direct human trials are limited, the trend aligns with animal studies showing reduced blastocyst formation rates. Clinics such as Shady Grove Fertility and Pacific Fertility Center now include cannabis screening in their pre-treatment labs, and some report lower success rates among active users. The FDA tracks emerging data on cannabis and reproductive outcomes.
Pregnancy Outcomes and Ongoing Risks
A 2024 CDC analysis of birth certificate data found that self-reported cannabis use during pregnancy was associated with a 1.3x higher risk of preterm birth and lower birth weight. The placenta expresses CB1 and CB2 receptors, and THC can cross the placental barrier, potentially affecting fetal growth and neurodevelopment. Companies including Everlywell and LetsGetChecked now offer at-home fertility and prenatal panels that flag cannabis metabolites. The CDC shares current data on substance use and pregnancy outcomes.
Post-2020 legalization waves have increased the potency of available cannabis products, with average THC concentrations rising above 20% in many legal markets. This shift complicates risk assessments, as higher potency may amplify endocrine disruption. Regulatory bodies such